Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2018 1
2020 1
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Né P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van Sluis P, Hakkert A, van Wezel E, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM. Eleveld TF, et al. Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333. Epub 2015 Jun 29. Nat Genet. 2015. PMID: 26121087 Free PMC article.
Eighteen of the 23 relapse tumors (78%) showed mutations predicted to activate the RAS-MAPK pathway. ...Our findings provide a rationale for genetic characterization of relapse neuroblastomas and show that RAS-MAPK
Eighteen of the 23 relapse tumors (78%) showed mutations predicted to activate the RAS-MAPK pathway. ...O …
NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.
Valencia-Sama I, Ladumor Y, Kee L, Adderley T, Christopher G, Robinson CM, Kano Y, Ohh M, Irwin MS. Valencia-Sama I, et al. Cancer Res. 2020 Aug 15;80(16):3413-3423. doi: 10.1158/0008-5472.CAN-19-3822. Epub 2020 Jun 25. Cancer Res. 2020. PMID: 32586982
However, at neuroblastoma recurrence, more frequent mutations in genes in the RAS-MAPK pathway have been detected. ...These results suggest for the first time that combination therapies targeting SHP2 and other components of the …
However, at neuroblastoma recurrence, more frequent mutations in genes in the RAS-MAPK pathway
RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.
Eleveld TF, Schild L, Koster J, Zwijnenburg DA, Alles LK, Ebus ME, Volckmann R, Tijtgat GA, van Sluis P, Versteeg R, Molenaar JJ. Eleveld TF, et al. Cancer Res. 2018 Nov 1;78(21):6297-6307. doi: 10.1158/0008-5472.CAN-18-1045. Epub 2018 Aug 16. Cancer Res. 2018. PMID: 30115695
Mutations affecting the RAS-MAPK pathway frequently occur in relapsed neuroblastoma tumors, which suggests that activation of this pathway is associated with a more aggressive phenotype. ...Mutation of PHOX2B and dele
Mutations affecting the RAS-MAPK pathway frequently occur in relapsed neuroblastoma tumors,
Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.
Malone CF, Kim M, Alexe G, Engel K, Forman AB, Robichaud A, Conway AS, Goodale A, Meyer A, Khalid D, Thayakumar A, Hatcher JM, Gray NS, Piccioni F, Stegmaier K. Malone CF, et al. Cancer Res. 2023 Jan 18;83(2):285-300. doi: 10.1158/0008-5472.CAN-21-4309. Cancer Res. 2023. PMID: 36398965 Free PMC article.
Aberrant RAS/MAPK signaling is a common driver of oncogenesis that can be therapeutically targeted with clinically approved MEK inhibitors. ...Here we focused on identifying MEK inhibitor-based combination therapies in neuroblastoma with mutations that …
Aberrant RAS/MAPK signaling is a common driver of oncogenesis that can be therapeutically targeted with clinically approved ME …
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma.
Eleveld TF, Vernooij L, Schild L, Koopmans B, Alles LK, Ebus ME, Dandis R, van Tinteren H, Caron HN, Koster J, van Noesel MM, Tytgat GAM, Eising S, Versteeg R, Dolman MEM, Molenaar JJ. Eleveld TF, et al. Front Oncol. 2023 Feb 21;13:1130034. doi: 10.3389/fonc.2023.1130034. eCollection 2023. Front Oncol. 2023. PMID: 36895472 Free PMC article.
INTRODUCTION: Mutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblastoma tumors and are associated with response to MEK inhibition in vitro. ...CONCLUSION: Together, these results show that combining MEK in …
INTRODUCTION: Mutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblasto